FDA approves pill with sensor that digitally tracks if patients have ingested their medication.
Summary
FDA approves Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication
Release
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.
The system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm